442 related articles for article (PubMed ID: 15919798)
21. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Ashraf MT; Ahmed Rizvi SH; Kashif MAB; Shakeel Khan MK; Ahmed SH; Asghar MS
Diabetes Obes Metab; 2023 Nov; 25(11):3377-3389. PubMed ID: 37580969
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?
Herold KC; Taylor L
Immunol Res; 2003; 28(2):141-50. PubMed ID: 14610290
[TBL] [Abstract][Full Text] [Related]
23. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.
Utset TO; Auger JA; Peace D; Zivin RA; Xu D; Jolliffe L; Alegre ML; Bluestone JA; Clark MR
J Rheumatol; 2002 Sep; 29(9):1907-13. PubMed ID: 12233885
[TBL] [Abstract][Full Text] [Related]
24. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
[TBL] [Abstract][Full Text] [Related]
25. Immune therapy and β-cell death in type 1 diabetes.
Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
[TBL] [Abstract][Full Text] [Related]
26. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
[TBL] [Abstract][Full Text] [Related]
27. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.
Cernea S; Herold KC
Clin Immunol; 2010 Feb; 134(2):121-9. PubMed ID: 19837003
[TBL] [Abstract][Full Text] [Related]
29. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
30. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
[TBL] [Abstract][Full Text] [Related]
31. Prolactin: An Effective Partner for Anti-CD3 in Treating Type 1 Diabetes.
Xiao X
Endocrinology; 2016 Jan; 157(1):39-41. PubMed ID: 26717470
[No Abstract] [Full Text] [Related]
32. [Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody].
Chatenoud L; Thervet E; Primo J; Bach JF
C R Acad Sci III; 1992; 315(6):225-8. PubMed ID: 1468025
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
[TBL] [Abstract][Full Text] [Related]
34. Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy.
Hyslop CM; Tsai S; Shrivastava V; Santamaria P; Huang C
Endocrinology; 2016 Jan; 157(1):150-65. PubMed ID: 26512750
[TBL] [Abstract][Full Text] [Related]
35. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study.
Ambery P; Donner TW; Biswas N; Donaldson J; Parkin J; Dayan CM
Diabet Med; 2014 Apr; 31(4):399-402. PubMed ID: 24236828
[TBL] [Abstract][Full Text] [Related]
37. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
38. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).
Zhou Z; Li X; Huang G; Peng J; Yang L; Yan X; Wang J
Diabetes Metab Res Rev; 2005; 21(2):203-8. PubMed ID: 15386806
[TBL] [Abstract][Full Text] [Related]
39. Effects of methylprednisolone pulse therapy on insulin injections in patients with insulin-dependent diabetes mellitus.
Satman I; Fiçicioğlu C; Karşidağ K; Yilmaz T; Dinçdağ N; Koca F; Odabaşi F; Aydin A; Devrim S; Haktan M
Turk J Pediatr; 1996; 38(4):419-29. PubMed ID: 8993171
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis.
Liu Y; Li W; Chen Y; Wang X
Endocrine; 2024 Feb; 83(2):322-329. PubMed ID: 37658243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
